Buy Crypto Markets Spot FuturesBTC Earn Event Center Rewards Hub

First Tracks Biotherapeutics, Inc. (TRAXV)

NASDAQ

$--

(--)

Market Closed

First Tracks Biotherapeutics, Inc. (TRAXV) Live Price Chart

Last updated: ⁦2026-09-06 18:54:00⁩. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.

Summary

First Tracks Biotherapeutics, Inc. (TRAXV) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	--
Open	--
Day's High	--
Day's Low	--
Previous Close	--
Volume	--
Average Volume	--
P/E Ratio	--
52-Week High	--
52-Week Low	--
Dividend Yield	--
Earnings Date	--

First Tracks Biotherapeutics, Inc. (TRAXV) Latest Closing Stock Price

First Tracks Biotherapeutics, Inc. (TRAXV) last closed at $-- as of --, -- from the previous close of $--.

During the latest regular trading session, TRAXV traded between $-- and $--, with a volume of -- shares. The closing price was -- and --.

First Tracks Biotherapeutics, Inc. (TRAXV) 7-Day Stock Price Change

Over the past seven days, First Tracks Biotherapeutics, Inc. (TRAXV) moved from $24.20 to $22.51, representing a decline of 6.98% ($1.69).

The stock traded between $21.77 and $26.80 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.

The average daily volume was 7.90 thousand shares, up versus the previous seven-day period, indicating higher trading activity.

What is First Tracks Biotherapeutics, Inc. (TRAXV)?

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

First Tracks Biotherapeutics, Inc. Information

Exchange

NASDAQ

How to Buy First Tracks Biotherapeutics, Inc. (TRAXV) Stock on MEXC

Eligible investors can buy real shares of First Tracks Biotherapeutics, Inc. (TRAXV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for TRAXV and Place Your Order

Open the RealStocks trading page and search for TRAXV. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is First Tracks Biotherapeutics, Inc. (TRAXV) stock price today?

First Tracks Biotherapeutics, Inc. (TRAXV) is currently trading at --, -- from the previous close of --. Intraday prices update in real time during regular trading hours.

2.Is TRAXV stock going up or down today?

As of --, TRAXV is trading at --, -- from its previous close of --. The stock has traded between -- and -- during today’s regular session. Past price movements do not guarantee future results.

3.What is TRAXV pre-market price?

As of --, TRAXV is trading at -- in pre-market trading, -- from the previous close of --. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is TRAXV after-hours price?

As of --, TRAXV is trading at -- in after-hours trading, -- from the regular-session close of --. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is TRAXV stock trading now?

TRAXV trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does TRAXV sit relative to its 52-week high and low?

Over the past 52 weeks, TRAXV has traded between a low of -- and a high of --. At --, the stock is positioned --% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is First Tracks Biotherapeutics, Inc. in?

First Tracks Biotherapeutics, Inc. (TRAXV) operates in the -- sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is First Tracks Biotherapeutics, Inc.'s market capitalization and where is it listed?

First Tracks Biotherapeutics, Inc. is listed on the NASDAQ exchange with a market capitalization of --. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is TRAXV valued in terms of P/E ratio and EPS?

TRAXV trades at a P/E ratio of --, based on trailing-twelve-month EPS of --. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does First Tracks Biotherapeutics, Inc. pay a dividend?

First Tracks Biotherapeutics, Inc. pays an indicated annual cash dividend of -- per share, with a current dividend yield of --% based on the latest share price. Dividend policies are subject to change at the board's discretion.